ClinicalTrials.gg
CompletedNCT05274269Updated Aug 1, 2024Results posted

Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation

A Phase 3 interventional study of ELX/TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 90 sites in 15 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2024-08-01.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
307
Allocation
Randomized
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing elexacaftor in Cystic Fibrosis — 2 open to participants now, 5 under way, 2 of them phase 3. elexacaftor · Cystic Fibrosis.

Enrollment
3rd of 23
307 · median 120
Started
2022
with 3 others
Phase 3
19 of 23
none open now
Registered
18th of 23
by date
Lead sponsor
20 of 23
Vertex Pharmaceuticals Incorporated

Among the 23 studies testing elexacaftor in Cystic Fibrosis, this one is the 3rd largest by enrollment, is one of 4 that started in 2022, is one of 19 in phase 3, and was the 18th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

2 of the 23 studies testing elexacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About elexacaftor

elexacaftor: first FDA approval 2019 (TRIKAFTA (COPACKAGED)), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing elexacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

This study evaluated the efficacy, pharmacodynamics (PD) and safety of ELX/TEZ/IVA in participants 6 years of age and older with a non-F508del ELX/TEZ/IVA-responsive cystic fibrosis transmembrane conductance regulator gene (CFTR) mutation.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant has a qualifying ELX/TEZ/IVA-responsive CFTR mutation and does not have an exclusionary CFTR mutation
  • (FEV1) value >=40% and \<=100% of predicted mean for age, sex, and height

Key Exclusion Criteria:

  • History of solid organ or hematological transplantation
  • cirrhosis with or without portal hypertension
  • Lung infection with organisms associated with a more rapid decline in pulmonary status

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
307 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo matched to ELX/TEZ/IVA FDC in the morning and placebo matched to IVA in the evening for 24 weeks.

    Other: Placebo (matched to ELX/TEZ/IVA) · Other: Placebo (matched to IVA)

  • Experimental
    ELX/TEZ/IVA

    Participants 6 to less than (\<) 12 years of age and weighing \<30 kilogram (kg) at Day 1 received ELX 100 milligram (mg)/TEZ 50 mg /IVA 75 mg as fixed dose combination (FDC) tablets in the morning and IVA as mono tablet in the evening and those weighing more than or equal to (≥) 30 kg at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks. Participants ≥12 years age at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks.

    Drug: ELX/TEZ/IVA · Drug: IVA

Interventions

  • DrugELX/TEZ/IVA

    Drug pages: Elexacaftor · Tezacaftor · Ivacaftor

    Fixed-dose combination (FDC) tablets for oral administration.

    Also known as: VX-445/VX-661/VX-770, elexacaftor/tezacaftor/ivacaftor

  • DrugIVA

    Tablet for oral administration.

    Also known as: VX-770, ivacaftor

  • OtherPlacebo (matched to ELX/TEZ/IVA)

    Placebo matched to ELX/TEZ/IVA for oral administration.

  • OtherPlacebo (matched to IVA)

    Placebo matched to IVA for oral administration.

06

What researchers measure

Primary outcomes

  1. Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: From Baseline Through Week 24

Secondary outcomes

  1. Absolute Change in Sweat Chloride (SwCl)

    Sweat samples were collected using an approved collection device.

    Time frame: From Baseline Through Week 24

  2. Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain (RD) Score

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

    Time frame: From Baseline Through Week 24

  3. Absolute Change in Body Mass Index (BMI)

    BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).

    Time frame: From Baseline at Week 24

  4. Absolute Change in Weight

    Time frame: From Baseline at Week 24

  5. Number of Pulmonary Exacerbations (PEx)

    Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.

    Time frame: From Baseline Through Week 24

  6. Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Week 28

07

Results

Posted Aug 1, 2024

Participant flow

This study was conducted in cystic fibrosis (CF) participants aged 6 years and older with a non-F508del ELX/TEZ/IVA-responsive cystic fibrosis transmembrane conductance regulator gene (CFTR) mutation.

Participant flow — Overall Study
MilestonePlaceboELX/TEZ/IVA
Started102205
Completed102197
Not completed08
Withdrew: Adverse event03
Withdrew: Death01
Withdrew: Other02
Withdrew: Withdrawal of consent (not due to ae)02

Outcome measures

PrimaryAbsolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
From Baseline Through Week 24
Reported as:
Least squares mean · percent predicted FEV1
Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
percent predicted FEV1PlaceboELX/TEZ/IVA
Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)-0.4 (-2.0 to 1.3)8.9 (7.7 to 10.0)
Statistical analysis
  • Placebo · Mixed Models for Repeated Measures · p = < 0.0001 · Ls mean difference: 9.2 · 95% CI 7.2 to 11.3
SecondaryAbsolute Change in Sweat Chloride (SwCl)

Sweat samples were collected using an approved collection device.

Time frame:
From Baseline Through Week 24
Reported as:
Least squares mean · millimole per liter (mmol/L)
Absolute Change in Sweat Chloride (SwCl)
millimole per liter (mmol/L)PlaceboELX/TEZ/IVA
Absolute Change in Sweat Chloride (SwCl)0.5 (-2.6 to 3.6)-27.8 (-30.0 to -25.6)
Statistical analysis
  • Placebo · Mixed Models for Repeated Measures · p = < 0.0001 · Ls mean difference: -28.3 · 95% CI -32.1 to -24.5
SecondaryAbsolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain (RD) Score

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

Time frame:
From Baseline Through Week 24
Reported as:
Least squares mean · units on a scale
Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain (RD) Score
units on a scalePlaceboELX/TEZ/IVA
Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain (RD) Score-2.0 (-5.2 to 1.3)17.5 (15.2 to 19.8)
Statistical analysis
  • Placebo · Mixed Models for Repeated Measures · p = < 0.0001 · Ls mean difference: 19.5 · 95% CI 15.5 to 23.5
SecondaryAbsolute Change in Body Mass Index (BMI)

BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).

Time frame:
From Baseline at Week 24
Reported as:
Least squares mean · kg/m^2
Absolute Change in Body Mass Index (BMI)
kg/m^2PlaceboELX/TEZ/IVA
Absolute Change in Body Mass Index (BMI)0.35 (0.16 to 0.53)0.81 (0.68 to 0.94)
Statistical analysis
  • Placebo · Mixed Models for Repeated Measures · p = < 0.0001 · Ls mean difference: 0.47 · 95% CI 0.24 to 0.69
SecondaryAbsolute Change in Weight
Time frame:
From Baseline at Week 24
Reported as:
Least squares mean · kilogram (kg)
Absolute Change in Weight
kilogram (kg)PlaceboELX/TEZ/IVA
Absolute Change in Weight1.2 (0.6 to 1.7)2.4 (2.1 to 2.8)
Statistical analysis
  • Placebo · Mixed Models for Repeated Measures · p = < 0.0001 · Ls mean difference: 1.3 · 95% CI 0.6 to 1.9
SecondaryNumber of Pulmonary Exacerbations (PEx)

Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.

Time frame:
From Baseline Through Week 24
Reported as:
Number · PEx events
Number of Pulmonary Exacerbations (PEx)
PEx eventsPlaceboELX/TEZ/IVA
Number of Pulmonary Exacerbations (PEx)4021
SecondarySafety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame:
Day 1 up to Week 28
Reported as:
Count of participants · Participants
Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPlaceboELX/TEZ/IVA
Participants with TEAEs97193
Participants with SAEs1518

Adverse events

Collected over Day 1 up to Week 28. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/102 (0%)15/102 (14.7%)86/102 (84.3%)
ELX/TEZ/IVA1/205 (0.5%)18/205 (8.8%)164/205 (80%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventPlaceboELX/TEZ/IVA
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations13/1025/205
Stress cardiomyopathyCardiac disorders1/1020/205
Drug intoleranceGeneral disorders1/1020/205
Renal colicRenal and urinary disorders1/1020/205
Bronchopulmonary aspergillosis allergicInfections and infestations0/1022/205
Abdominal painGastrointestinal disorders0/1021/205
PancreatitisGastrointestinal disorders0/1021/205
SubileusGastrointestinal disorders0/1021/205
Cholecystitis acuteHepatobiliary disorders0/1021/205
GastroenteritisInfections and infestations0/1021/205
Most frequent other events
Showing 10 of 20
Most frequent other events
EventPlaceboELX/TEZ/IVA
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations36/10228/205
CoughRespiratory, thoracic and mediastinal disorders26/10236/205
RashSkin and subcutaneous tissue disorders1/10245/205
NasopharyngitisInfections and infestations20/10242/205
HeadacheNervous system disorders13/10237/205
PyrexiaGeneral disorders14/10227/205
Abdominal painGastrointestinal disorders13/10217/205
Sputum increasedRespiratory, thoracic and mediastinal disorders13/10220/205
DiarrhoeaGastrointestinal disorders10/10226/205
COVID-19Infections and infestations10/10219/205

Baseline characteristics

All participants who received at least one dose of the study drug were included in the baseline analysis.

Age, Continuous
Age, Continuous(years)PlaceboELX/TEZ/IVATotal
Mean33.9 ± 16.433.3 ± 15.933.5 ± 16.0
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboELX/TEZ/IVATotal
Female52113165
Male5092142
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboELX/TEZ/IVATotal
Hispanic or Latino3811
Not Hispanic or Latino88171259
Not Collected per Local Regulations112637
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboELX/TEZ/IVATotal
White86172258
Asian246
Other134
Not Collected per Local Regulations122638
White, Asian101
Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)(percent predicted FEV1)PlaceboELX/TEZ/IVATotal
Mean68.1 ± 18.167.5 ± 17.667.7 ± 17.7
08

Study locations

90 sites
  • Medizinische Universität Innsbruck
    Innsbruck, Austria
  • Cliniques Universitaires de Bruxelles Hopital Erasme
    Brussels, Belgium
  • Universitair Ziekenhuis Brussel - Campus Jette
    Brussels, Belgium
  • Universitair Ziekenhuis Antwerpen (UZA) - Antwerp University Hospital
    Edegem, Belgium
  • Universitair Ziekenhuis Gent
    Gent, Belgium
  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
    Leuven, Belgium
  • Cliniques Universitaires Saint-Luc
    Woluwe-Saint-Lambert, Belgium
  • Stollery Children's Hospital
    Edmonton, Canada
  • Centre Hospitalier de l'Universite de Montreal (CHUM) Hotel-Dieu
    Montreal, Canada
  • McGill University Health Centre, Glen Site, Montreal Children's Hospital
    Montreal, Canada
  • The Hospital for Sick Children
    Toronto, Canada
  • British Columbia Children's Hospital
    Vancouver, Canada
  • St. Paul's Hospital
    Vancouver, Canada
  • Klinika Detskych Infekcnich Nemoci
    Brno, Czechia
  • Fakultni nemocnice v Motole
    Praha 5, Czechia
  • CHU Lyon - Hopital Femme Mere-Enfant
    Bron Cedex, France
  • Centre Hospitalier Intercommunal Creteil
    Créteil, France
  • Institut Cœur Poumon, CHU de Lille
    Lille, France
  • CHU Marseille - Hopital Nord
    Marseille, France
  • Hopital Arnaud de Villeneuve
    Montpellier Cedex 5, France
  • Centre Hospitalier Universitaire De Nantes - G. R. Laennec
    Nantes, France
  • Centre Hospitalier Universitaire (CHU) de Nice - Hopital Pasteur
    Nice, France
  • Hopital Necker, Enfants Malades
    Paris Cedex 15, France
  • Hopital Cochin
    Paris, France
  • Hopital Robert Debre
    Paris, France
  • Hopital Haut-Leveque - CRCM Adulte
    Pessac, France
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite, France
  • Centre Hospitalier Universitaire De Reims, Hopital Sebastopol
    Reims, France
  • CHU de Rennes - Hôpital Sud
    Rennes, France
  • Centre de Perharidy
    Roscoff Cedex, France
  • CHU de Toulouse - Hopital Larre
    Toulouse, France
  • Hopital Bretonneau
    Tours, France
  • Charite Paediatric Pulmonology Department
    Berlin, Germany
  • Friedrich-Alexander University of Erlangen-Nuremberg, University Children's Hospital
    Erlangen, Germany
  • Ruhrlandklinik Westdeutsches Lungenzentrum am Klinikum Essen
    Essen, Germany
  • Johann Wolfgang Goethe University
    Frankfurt, Germany
  • Justus-Liebig-Universität Gießen Zentrum für Kinderheilkunde und Jugendmedizin
    Gießen, Germany
  • Universitätsklinikum Halle (Saale) / Universitätsklinik und Poliklinik für Innere Medizin, Schwerpunkt Pneumologie
    Halle, Germany
  • Hannover Medical School
    Hannover, Germany
  • Medizinische Hochschule Hannover
    Hannover, Germany
  • Universitaetsklinikum Jena, Mukoviszidose-Zentrum
    Jena, Germany
  • Universitaetsklinkum Koeln, CF-Studienzentrum
    Koeln, Germany
  • Johannes Gutenberg-Universitaet
    Mainz, Germany
  • Pneumologisches Studienzentrum Muenchen-West
    Muenchen, Germany
  • Dr. von Haunersches Kinderspital
    München, Germany
  • Klinikum Innenstadt, University of Munich
    München, Germany
  • Klinik fur Kinder- und Jugendmedizin, Universitatsklinikum Munster
    Münster, Germany
  • Klinikum Westbrandenburg (CF)
    Potsdam, Germany
  • Universitätsklinikum Tübingen Klinik für Kinder- und Jugendmedizin
    Tuebingen, Germany
  • Universitätsklinikum Ulm, Klinik für Kinder- und Jugendmedizin (CF)
    Ulm, Germany
  • Universitätsklinikum Würzburg
    Würzburg, Germany
  • National Koranyi Institute for TBC and Pulmonology
    Budapest, Hungary
  • Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona
    Ancona, Italy
  • Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer
    Firenze, Italy
  • IRCCS Istituto Giannina Gaslini-Ospedale Pediatrico
    Genova, Italy
  • Azienda Ospedaliera Universitaria Policlinico G. Martino
    Messina, Italy
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milano, Italy
  • Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena
    Milan, Italy
  • Azienda Ospedaliera Universitaria Federico II (Adults)
    Naples, Italy
  • Malattie Apparato Respiratorio 2 - Centro Fibrosi Cistica
    Orbassano, Italy
  • Centro Regionale Fibrosi Cistica, A.O. Ospedale San Carlo
    Potenza, Italy
  • Ospedale Pediatrico Bambino Gesu
    Rome, Italy
  • Azienda Ospedaliera di Verona - Ospedale Civile Maggiore
    Verona, Italy
  • Academisch Medisch Centrum (Academic Medical Centre)
    Amsterdam, Netherlands
  • HagaZiekenhuis van den Haag
    Den Haag, Netherlands
  • UMC St. Radboud
    Nijmegen, Netherlands
  • Erasmus Medical Center
    Rotterdam, Netherlands
  • Universitair Medisch Centrum Utrecht
    Utrecht, Netherlands
  • Oslo University Hospital, Department of Paediatric Medicine
    Oslo, Norway
  • Pediatric Hospital Polanki named of Maciej Płażyński
    Gdańsk, Poland
  • Institute of Tuberculosis and Lung Diseases
    Rabka-Zdrój, Poland
  • Instytut Matki i Dziecka, Klinika Mukowiscydozy IMiD, Oddział Chorób Płuc SZPZOZ im.Dzieci Warszawy w Dziekanowie Leśnym
    Łomianki, Poland
  • Hospital de Santa Maria
    Lisbon, Portugal
  • Hospital Sao Joao
    Porto, Portugal
  • Hospital de Cruces
    Barakaldo, Spain
  • Hospital Saint Joan de Deu
    Barcelona, Spain
  • Hospital Universitari Vall d Hebron
    Barcelona, Spain
  • Hospital Universitari Vall d´Hebron Servicio de Broncoscopia
    Barcelona, Spain
  • Hospital Universitario de Jerez de la Frontera
    Jerez De La Frontera, Spain
  • Hospital Infantil Universitario Nino Jesus
    Madrid, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, Spain
  • Hospital Universitario Infantil La Paz
    Madrid, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, Spain
  • Hospital Virgen de la Arrixaca
    Murcia, Spain
  • Corporacio Sanitaria Parc Tauli - Sabadell Hospital Universitari
    Sabadell, Spain
  • Hospital Universitario Virgen del Rocio
    Sevilla, Spain
  • Hospital Universitario y Politecnico La Fe
    Valencia, Spain
  • Sahlgrenska Universitetssjukhuset
    Göteborg, Sweden
  • Karolinska Universitetssjukhuset, Huddinge
    Stockholm, Sweden
  • Kinderspital Zuerich
    Zurich, Switzerland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Jul 2023, 13 months.

Results were first posted in Aug 2024, 1 year after primary completion.

Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 13 months is below that.

Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2022
First posted
Mar 10, 2022
StartActual
May 9, 2022
Primary completionActual
Jul 5, 2023
CompletionActual
Jul 5, 2023
Results first posted
Aug 1, 2024
Last update
Aug 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05274269
Responsible party
Sponsor
First posted
Mar 10, 2022
Start date
May 9, 2022
Primary completion
Jul 5, 2023
Completion
Jul 5, 2023
Results posted
Aug 1, 2024
Last update
Aug 1, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elexacaftor · Tezacaftor · Ivacaftor

Start the discussion